The Star Formation Across Cosmic Time (SFACT) Survey. II. The First Catalog from a New Narrow-Band Survey for Emission-Line Objects

Star Formation Across Cosmic Time (SFACT) is a new narrowband survey designed to detect faint emission-line galaxies and QSOs over a broad range of redshifts. Here we present the first list of SFACT candidates from our pilot-study fields. Using the WIYN 3.5m telescope, we are able to achieve good image quality with excellent depth and routinely detect ELGs to r = 25.0. The limiting line flux of the survey is ~1.0 x 10^16 erg/s/cm^2. SFACT targets three primary emission lines: H-alpha, [O III]5007, and [O II]3727. The corresponding redshift windows allow for the detection of objects at z ~ 0-1. With a coverage of 1.50 square degrees in our three pilot-study fields, a total of 533 SFACT candidates have been detected (355 candidates per square degree). We detail the process by which these candidates are selected in an efficient and primarily automated manner, then tabulate accurate coordinates, broadband photometry, and narrowband fluxes for each source.Comment: 26 pages, 12 figures. Accepted for publication in the Astronomical Journa

The Star Formation Across Cosmic Time (SFACT) Survey. I. Survey Description and Early Results from a New Narrow-Band Emission-Line Galaxy Survey

We introduce the Star Formation Across Cosmic Time (SFACT) survey. SFACT is a new narrow-band survey for emission-line galaxies (ELGs) and QSOs being carried out using the wide-field imager on the WIYN 3.5 m telescope. Because of the superior depth and excellent image quality afforded by WIYN, we routinely detect ELGs to r = 25.0. Our survey observations are made using three custom narrow-band filters centered on 6590 A, 6950 A, and 7460 A. Due to the sensitivity of the survey, we are able to simultaneously detect sources via a number of different emission lines over a wide range of redshifts. The principal lines detected in SFACT are H-alpha (redshifts up to 0.144), [O III]5007 (redshifts up to 0.500) and [O II]3727 (redshifts up to 1.015). In this paper we detail the properties of the survey as well as present initial results obtained by analyzing our three pilot-study fields. These fields have yielded a total of 533 ELG candidates in an area of 1.50 square degrees (surface density of 355 ELGs per square degree). Follow-up spectra for a subset of the ELG candidates are also presented. One of the key attributes of the SFACT survey is that the ELGs are detected in discrete redshift windows that will allow us to robustly quantify the properties of the star-forming and AGN populations as a function of redshift to z = 1 and beyond. The planned acquisition of additional narrow-band filters will allow us to expand our survey to substantially higher redshifts.Comment: 27 pages, 13 figures. Accepted for publication in the Astronomical Journa

Nanoparticle-mediated targeting of MAPK signaling predisposes tumor to chemotherapy

The MAPK signal transduction cascade is dysregulated in a majority of human tumors. Here we report that a nanoparticle-mediated targeting of this pathway can optimize cancer chemotherapy. We engineered nanoparticles from a unique hexadentate-polyD,L-lactic acid-co-glycolic acid polymer chemically conjugated to PD98059, a selective MAPK inhibitor. The nanoparticles are taken up by cancer cells through endocytosis and demonstrate sustained release of the active agent, resulting in the inhibition of phosphorylation of downstream extracellular signal regulated kinase. We demonstrate that nanoparticle-mediated targeting of MAPK inhibits the proliferation of melanoma and lung carcinoma cells and induces apoptosis in vitro. Administration of the PD98059-nanoparticles in melanoma-bearing mice inhibits tumor growth and enhances the antitumor efficacy of cisplatin chemotherapy. Our study shows the nanoparticle-mediated delivery of signal transduction inhibitors can emerge as a unique paradigm in cancer chemotherapy.Department of Defense Breast Cancer Research Program Era of Hope Award (W81XWH-07–1-0482)Mary Kay Ash Charitable Trus

Неразрушающий контроль. Т. 3

В сборнике представлен широкий круг исследований аспирантов, студентов и молодых ученых Томска и других городов России. Сборник посвящен теоретическим и практическим аспектам неразрушающего контроля

Mutated CTSF in adult-onset neuronal ceroid lipofuscinosis and FTD

OBJECTIVE: To investigate the molecular basis of a Belgian family with autosomal recessive adult-onset neuronal ceroid lipofuscinosis (ANCL or Kufs disease [KD]) with pronounced frontal lobe involvement and to expand the findings to a cohort of unrelated Belgian patients with frontotemporal dementia (FTD). METHODS: Genetic screening in the ANCL family and FTD cohort (n = 461) was performed using exome sequencing and targeted massive parallel resequencing. RESULTS: We identified a homozygous mutation (p.Ile404Thr) in the Cathepsin F (CTSF) gene cosegregating in the ANCL family. No other mutations were found that could explain the disease in this family. All 4 affected sibs developed motor symptoms and early-onset dementia with prominent frontal features. Two of them evolved to akinetic mutism. Disease presentation showed marked phenotypic variation with the onset ranging from 26 to 50 years. Myoclonic epilepsy in one of the sibs was suggestive for KD type A, while epilepsy was not present in the other sibs who presented with clinical features of KD type B. In a Belgian cohort of unrelated patients with FTD, the same heterozygous p.Arg245His mutation was identified in 2 patients who shared a common haplotype. CONCLUSIONS: A homozygous CTSF mutation was identified in a recessive ANCL pedigree. In contrast to the previous associations of CTSF with KD type B, our findings suggest that CTSF genetic testing should also be considered in patients with KD type A as well as in early-onset dementia with prominent frontal lobe and motor symptoms

SMER28 attenuates PI3K/mTOR signaling by direct inhibition of PI3K p110 delta

SMER28 (Small molecule enhancer of Rapamycin 28) is an autophagy-inducing compound functioning by a hitherto unknown mechanism. Here, we confirm its autophagy-inducing effect by assessing classical autophagy-related parameters. Interestingly, we also discovered several additional effects of SMER28, including growth retardation and reduced G1 to S phase progression. Most strikingly, SMER28 treatment led to a complete arrest of receptor tyrosine kinase signaling, and, consequently, growth factor-induced cell scattering and dorsal ruffle formation. This coincided with a dramatic reduction in phosphorylation patterns of PI3K downstream effectors. Consistently, SMER28 directly inhibited PI3Kδ and to a lesser extent p110γ. The biological relevance of our observations was underscored by SMER28 interfering with InlB-mediated host cell entry of Listeria monocytogenes, which requires signaling through the prominent receptor tyrosine kinase c-Met. This effect was signaling-specific, since entry of unrelated, gram-negative Salmonella Typhimurium was not inhibited. Lastly, in B cell lymphoma cells, which predominantly depend on tonic signaling through PI3Kδ, apoptosis upon SMER28 treatment is profound in comparison to non-hematopoietic cells. This indicates SMER28 as a possible drug candidate for the treatment of diseases that derive from aberrant PI3Kδ activity

Psammocarcinoma of ovary with serous cystadenofibroma of contralateral ovary: a case report

<p>Abstract</p> <p>Introduction</p> <p>Psammocarcinoma of ovary is a rare serous neoplasm characterized by extensive formation of psammoma bodies, invasion of ovarian stroma, peritoneum or intraperitoneal viscera, and moderate cytological atypia. Extensive medlar search showed presence of only 28 cases of psammocarcinoma of ovary reported till date.</p> <p>Case presentation</p> <p>We herein report a case of psammocarcinoma of ovary with serous cystadenofibroma of contralateral ovary in a 55 year old Asian Indian female.</p> <p>Conclusion</p> <p>To the best of author's knowledge, ours is the rare case describing coexistence of this very rare malignant serous epithelial tumor with a benign serous cystadenofibroma of contralateral ovary.</p

Association of decreased mitochondrial DNA content with ovarian cancer progression

Mitochondrial DNA (mtDNA) content in ovarian carcinomas was assessed by quantitative PCR. Results show that mtDNA content in tumour cell was significantly higher than that in normal ovary. Change in mtDNA content was not related with patients' age or tumour stages. However, the average mtDNA copy number in pathological low-grade tumours was over two-fold higher than that in high-grade carcinomas (P=0.012). Moreover, type I carcinomas also had a significantly higher mtDNA copy number than in type II carcinomas (P=0.019). Change in mtDNA content might be an important genetic event in the progression of ovarian carcinomas